9 in 10 individual F&O traders made net losses (SEBI).Risk disclosures on derivatives: 9 out of 10 individual traders in equity F&O incurred net losses.Read more

9 out of 10 individual traders in equity Futures and Options Segment incurred net losses.
On an average, loss makers registered net trading loss close to ₹50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein aggregate level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22. SEBI’s latest study (August 2026) found that 87.7% of individual traders in equity derivatives made net losses in FY 2025-26.

LAURUSLABS max painexpiry 23 Nov 2026

Key facts

LAURUSLABS max pain for the 23 Nov 2026 expiry is 2,280, 7.1% below the spot of ₹2,454.00, as of 9 Nov 2026, 3:40 pm IST. Over the last 52 settled expiries, LAURUSLABS settled within ±1% of the max pain read the session before 12% of the time.

Max pain: 2,280
Share price: ₹2,454.00
Gap to max pain: 7.1% below the spot
Expiry: 23 Nov (14 days)
Settled within ±1%: 12% of 52
Highest call OI: 2,500
Highest put OI: 2,000
PCR (OI): 0.86

As of 9 Nov 2026, 3:40 pm IST · End-of-day figures from the 9 Nov 2026 session; they refresh after the next close.

Open the expiry and max pain tool →Every strike, greeks and past sessions.

LAURUSLABS max pain by strike, 23 Nov 2026 expiry

What option writers would pay out if LAURUSLABS settled at each strike, in rupees, from the open interest of the 50 strikes nearest the money. Max pain (2,280) is the lowest total over every listed strike.
Settlement at	Call writers pay	Put writers pay	Total payout
2,080	₹19.47 Cr	₹136 Cr	₹155 Cr
2,100	₹22.68 Cr	₹123 Cr	₹145 Cr
2,120	₹26.92 Cr	₹111 Cr	₹138 Cr
2,140	₹31.35 Cr	₹100 Cr	₹132 Cr
2,160	₹36.10 Cr	₹89.60 Cr	₹126 Cr
2,180	₹41.09 Cr	₹79.15 Cr	₹120 Cr
2,200	₹46.30 Cr	₹69.06 Cr	₹115 Cr
2,220	₹52.38 Cr	₹60.55 Cr	₹113 Cr
2,240	₹58.62 Cr	₹52.25 Cr	₹111 Cr
2,260	₹65.26 Cr	₹44.35 Cr	₹110 Cr
2,280max pain	₹72.30 Cr	₹36.92 Cr	₹109 Cr
2,300	₹79.66 Cr	₹29.93 Cr	₹110 Cr
2,320	₹88.07 Cr	₹24.66 Cr	₹113 Cr
2,340	₹97.03 Cr	₹19.83 Cr	₹117 Cr
2,360	₹106 Cr	₹15.46 Cr	₹122 Cr
2,380	₹117 Cr	₹11.48 Cr	₹128 Cr
2,400	₹127 Cr	₹7.90 Cr	₹135 Cr
2,420	₹139 Cr	₹6.05 Cr	₹145 Cr
2,440	₹152 Cr	₹4.47 Cr	₹157 Cr
2,460	₹166 Cr	₹3.24 Cr	₹170 Cr
2,480	₹181 Cr	₹2.24 Cr	₹183 Cr

LAURUSLABS max pain by expiry

Each listed expiry's open interest, put-call ratio and max pain, 9 Nov 2026 session. OI in contracts.
Expiry	Days left	Call OI	Put OI	PCR	Max pain	ATM IV
23 Nov 2026	13	25.8 K	23.0 K	0.89	2,300	31.7%
29 Dec 2026	49	1.3 K	1.1 K	0.81	2,320	28.5%
25 Jan 2027	76	4	0	0.00	2,520	23.8%

Frequently asked questions

What is LAURUSLABS max pain today?

LAURUSLABS max pain for the 23 Nov 2026 expiry is 2,280 as of 9 Nov 2026, 3:40 pm IST, 7.1% below the spot of ₹2,454.00.

How is max pain calculated?

For every strike, add up what all open calls and puts would be worth at expiry if LAURUSLABS settled exactly there (open interest × how far each option is in the money). Max pain is the strike where that total is smallest: the settlement at which option writers as a group would pay out the least. It is computed over every listed strike of the expiry.

Does LAURUSLABS expire at max pain?

Not reliably. Over the last 52 settled LAURUSLABS expiries (28 Jul 2022 to 27 Oct 2026), the settlement landed within ±1% of the max pain read on the last full session before expiry 12% of the time, and within ±0.5% 10% of the time.

Is max pain a trading signal?

No. It describes where open positions sit, not where the price will go, and it moves as positions change during the session. Nothing on this page is a recommendation to buy or sell.

Is this a recommendation to trade LAURUSLABS options?

No. Jivani Markets is not a SEBI-registered research analyst or investment adviser. These are exchange figures shown for research; nothing here is a recommendation to buy or sell. F&O trading carries high risk: SEBI found 87.7% of individual traders in equity derivatives made net losses in FY 2025-26.

Not investment advice. Jivani Markets is a technology platform, not a SEBI-registered investment adviser or research analyst.

Derivatives are leveraged and can lose more than the premium or margin put in. Strategy results here are hypothetical. Past performance is not indicative of future results. Not investment advice. Jivani Markets is a technology platform, not a SEBI-registered investment adviser or research analyst.

Loading…